Dibondrin - Ampullen

DRUG2 trials

Sponsors

Rheacell GmbH & Co. KG, Medical University Of Vienna

Conditions

Negative and depressive symptoms in schizophrenia / schizoaffective disorderRecessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epidermolysis Bullosa (JEB)

Phase 3

A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB)

RecruitingCTIS2022-500266-10-00

Rheacell GmbH & Co. KGRecessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epidermolysis Bullosa (JEB)

Start: 2023-06-13Target: 119Updated: 2025-12-02

Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study.

RecruitingCTIS2024-519097-39-01

Medical University Of ViennaNegative and depressive symptoms in schizophrenia / schizoaffective disorder

Start: 2022-06-23Target: 20Updated: 2025-02-27